{"id":"gw815sf-hfa-mdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines fluticasone propionate (ICS) to reduce airway inflammation and beclomethasone or similar LABA component to provide bronchodilation and symptom relief. The HFA (hydrofluoroalkane) propellant formulation enables efficient delivery to the lungs via MDI, providing dual anti-inflammatory and bronchodilatory effects for chronic obstructive airway diseases.","oneSentence":"GW815SF is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via pressurized metered-dose inhaler for maintenance treatment of asthma and COPD.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:49.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of COPD"}]},"trialDetails":[{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["salmeterol/fluticasone propionate combination"],"phase":"phase_3","status":"active","brandName":"GW815SF HFA MDI","genericName":"GW815SF HFA MDI","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GW815SF is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via pressurized metered-dose inhaler for maintenance treatment of asthma and COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}